Literature DB >> 23530560

POU domain transcription factor BRN2 is crucial for expression of ASCL1, ND1 and neuroendocrine marker molecules and cell growth in small cell lung cancer.

Jun Ishii1, Hanako Sato, Masashi Sakaeda, Yukiko Shishido-Hara, Chie Hiramatsu, Hiroshi Kamma, Hiroaki Shimoyamada, Masachika Fujiwara, Tetsuya Endo, Ichiro Aoki, Takuya Yazawa.   

Abstract

BRN2 is a developmental neural cell-specific POU domain transcription factor and is crucial for cell lineage determination. We investigated the importance of BRN2 in the expression of the lineage-specific transcription factors (achaete-scute homolog-like 1 (ASCL1) and NeuroD1 (ND1)) and neural/neuroendocrine marker molecules (neural cell adhesion molecule 1 (NCAM1), synaptophysin (SYP) and chromogranin A (CHGA)) in small cell lung cancer (SCLC) using cultured lung cancer cells. All examined SCLC cell lines expressed BRN2, as well as ASCL1, ND1, NCAM1, SYP and CHGA. The expression levels of ASCL1, ND1, NCAM1, SYP and CHGA considerably decreased when BRN2 was knocked down in SCLC cells, and the addition of a BRN2 transgene into non-SCLC (NSCLC) cells induced the expression of ASCL1, ND1, NCAM1, SYP and CHGA. However, the BRN2 gene was not activated by the forced expression of ASCL1 or ND1 in NSCLC cells. The knockdown of BRN2 caused significant growth retardation with decrease of S to G2 phase population and mitotic cell rates and unaltered Ki-67-labeled or apoptotic cell rates in SCLC cells, indicating increase of G1 phase population. These findings suggest that BRN2 is a higher level regulator than ASCL1 and ND1 and BRN2 might be involved in aggressiveness of SCLC.
© 2013 The Authors. Pathology International © 2013 Japanese Society of Pathology and Wiley Publishing Asia Pty Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23530560     DOI: 10.1111/pin.12042

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  17 in total

1.  Epigenomic Profiling Discovers Trans-lineage SOX2 Partnerships Driving Tumor Heterogeneity in Lung Squamous Cell Carcinoma.

Authors:  Takashi Sato; Seungyeul Yoo; Ranran Kong; Abhilasha Sinha; Prashanth Chandramani-Shivalingappa; Ayushi Patel; Maya Fridrikh; Osamu Nagano; Takashi Masuko; Mary Beth Beasley; Charles A Powell; Jun Zhu; Hideo Watanabe
Journal:  Cancer Res       Date:  2019-09-24       Impact factor: 12.701

Review 2.  Cellular plasticity and the neuroendocrine phenotype in prostate cancer.

Authors:  Alastair H Davies; Himisha Beltran; Amina Zoubeidi
Journal:  Nat Rev Urol       Date:  2018-02-20       Impact factor: 14.432

Review 3.  Transcriptional deregulation underlying the pathogenesis of small cell lung cancer.

Authors:  Dong-Wook Kim; Keun-Cheol Kim; Kee-Beom Kim; Colin T Dunn; Kwon-Sik Park
Journal:  Transl Lung Cancer Res       Date:  2018-02

4.  Utility of secretagogin as a marker for the diagnosis of lung neuroendocrine carcinoma.

Authors:  Yigit Baykara; Ying Xiao; Dongfang Yang; Evgeny Yakirevich; Sara Maleki; Maria Garcia-Moliner; Li Juan Wang; Chiung-Kuei Huang; Shaolei Lu
Journal:  Virchows Arch       Date:  2022-03-31       Impact factor: 4.064

5.  Endocrine secretory granule production is caused by a lack of REST and intragranular secretory content and accelerated by PROX1.

Authors:  Jun Ishii; Hanako Sato-Yazawa; Korehito Kashiwagi; Kazuhiko Nakadate; Masami Iwamoto; Kakeru Kohno; Chie Miyata-Hiramatsu; Meitetsu Masawa; Masato Onozaki; Shuhei Noda; Tadasuke Miyazawa; Megumi Takagi; Takuya Yazawa
Journal:  J Mol Histol       Date:  2022-01-30       Impact factor: 3.156

6.  Impact of Gender in Renal Cell Carcinoma: The Relationship of FABP7 and BRN2 Expression with Overall Survival.

Authors:  Cheng Tan; Tatsuya Takayama; Naohisa Takaoka; Hiromi Fujita; Miki Miyazaki; Takayuki Sugiyama; Seiichiro Ozono
Journal:  Clin Med Insights Oncol       Date:  2014-02-23

7.  Identification of FBXL4 as a Metastasis Associated Gene in Prostate Cancer.

Authors:  Elzbieta Stankiewicz; Xueying Mao; D Chas Mangham; Lei Xu; Marc Yeste-Velasco; Gabrielle Fisher; Bernard North; Tracy Chaplin; Bryan Young; Yuqin Wang; Jasmin Kaur Bansal; Sakunthala Kudahetti; Lucy Spencer; Christopher S Foster; Henrik Møller; Peter Scardino; R Tim Oliver; Jonathan Shamash; Jack Cuzick; Colin S Cooper; Daniel M Berney; Yong-Jie Lu
Journal:  Sci Rep       Date:  2017-07-11       Impact factor: 4.379

8.  Extracellular signal-regulated kinase mediates chromatin rewiring and lineage transformation in lung cancer.

Authors:  Yusuke Inoue; Ana Nikolic; Dylan Farnsworth; Rocky Shi; Fraser D Johnson; Alvin Liu; Marc Ladanyi; Romel Somwar; Marco Gallo; William W Lockwood
Journal:  Elife       Date:  2021-06-14       Impact factor: 8.140

9.  BRN2 is a non-canonical melanoma tumor-suppressor.

Authors:  Michael Hamm; Pierre Sohier; Valérie Petit; Jérémy H Raymond; Véronique Delmas; Madeleine Le Coz; Franck Gesbert; Colin Kenny; Zackie Aktary; Marie Pouteaux; Florian Rambow; Alain Sarasin; Nisamanee Charoenchon; Alfonso Bellacosa; Luis Sanchez-Del-Campo; Laura Mosteo; Martin Lauss; Dies Meijer; Eirikur Steingrimsson; Göran B Jönsson; Robert A Cornell; Irwin Davidson; Colin R Goding; Lionel Larue
Journal:  Nat Commun       Date:  2021-06-17       Impact factor: 14.919

10.  Novel genes upregulated when NOTCH signalling is disrupted during hypothalamic development.

Authors:  Leslie Ratié; Michelle Ware; Frédérique Barloy-Hubler; Hélène Romé; Isabelle Gicquel; Christèle Dubourg; Véronique David; Valérie Dupé
Journal:  Neural Dev       Date:  2013-12-23       Impact factor: 3.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.